David Lubner is a seasoned finance executive with 30 years of experience in the life sciences industry. Mr. Lubner served as executive vice president and chief financial officer (CFO) of Ra Pharmaceuticals, acquired by UCB in 2020. Prior to that, he was CFO of Tetraphase Pharmaceuticals and was previously CFO of PharMetrics until it was acquired by IMS Health. He also held the CFO position at ProScript, where VELCADE^®, a therapy widely used for the treatment of multiple myeloma, was discovered.  Mr. Lubner currently serves on the boards of directors of Arcellx, Cargo Therapeutics, Dyne Therapeutics and Vor Biopharma as well as several private companies. He previously served on the board of directors of Nightstar Therapeutics, until it was acquired by Biogen, and Point Biopharma, until its acquisition by Eli Lilly & Company.  Mr. Lubner received his BS in business administration from Northeastern University and an MS in taxation from Bentley University.

Joshua Brumm joined Crescent as chief executive officer (CEO) in March 2025, bringing extensive experience in building and leading companies in biotech and healthcare. Previously, he was a general partner at Forbion, and from 2019 to 2024, he was president and CEO of Dyne Therapeutics, where he led the company through its initial public offering (IPO) and advanced two rare muscle disease programs to positive data demonstrating clinical proof-of-concept. Prior to that, he served as chief operating officer (COO) and chief financial officer (CFO) of Kaleido Biosciences as well as Versartis, leading both companies through their IPOs while progressing their product candidates through clinical development. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics, an oncology company that was ultimately acquired by AbbVie; CFO at ZELTIQ Aesthetics, where he led the company through its IPO and the international product launch for CoolSculpting; and director of finance at Proteolix, an oncology company, assisting in its sale to Onyx Pharmaceuticals. He also held investment banking positions at Citigroup Global Markets and Morgan Stanley.

Over the course of his career, Mr. Brumm has led four companies to their public listings, held senior leadership positions in three companies that were acquired and raised nearly $3 billion in capital. He currently serves on the board of AIRNA, is chairman of the board of Amphista Therapeutics and is a venture partner at Forbion, a leading life sciences investment firm. Mr. Brumm holds a BA in business administration from the University of Notre Dame.

Jonathan Violin, Ph.D. is a venture partner at Fairmount Funds and previously served as interim chief executive officer of Crescent from October 2024 to March 2025. Prior to that, Dr. Violin served as president and chief operating officer, and later chief executive officer, of Viridian Therapeutics (formerly Miragen Therapeutics). Dr. Violin also co-founded Quellis Biosciences, which was acquired by Catabasis Pharmaceuticals in 2021, as well as Dianthus Therapeutics. He also served in various roles at Trevana, as well as holding various consultancy roles to life science companies throughout his career. Dr. Violin earned a Ph.D. in pharmacology from the University of California, San Diego. He also earned an MBA with a concentration in health sector management and a BS in chemical pharmacology from Duke University.

Susan Moran, M.D. most recently served as chief medical officer of RayzeBio, until its acquisition in 2024 by Bristol Myers Squibb. Dr. Moran currently serves on the board of directors of Tyra Biosciences and BioAtla, both publicly traded clinical-stage biotechnology companies. She was previously chief medical officer at QED Therapeutics and prior to that, led clinical development at Puma Biotechnology. Dr. Moran received an M.D. from Duke University, and an MS in clinical epidemiology from the University of Pennsylvania School of Medicine. She received a BA in chemistry from the University of Virginia.

Alex Balcom is currently chief financial officer of Nuvalent. Prior to joining Nuvalent, she served as vice president of finance at SQZ Biotechnologies, where she helped raise more than $200 million in private and public equity financing, including the company’s 2020 initial public offering. Previously, Ms. Balcom served as corporate controller at Agios Pharmaceuticals, supporting more than $700 million in equity financing. She earned a BBA in finance from the University of Massachusetts, Amherst, and an MBA from Boston College. She is also a certified public accountant in Massachusetts.

Peter Harwin is a managing member at Fairmount Funds Management, a healthcare investment firm he co-founded in 2016. Prior to Fairmount, he was a member of the investment team at Boxer Capital, an investment fund that was part of the Tavistock Group, based in San Diego. Mr. Harwin also serves as chairman of the board of directors of Cogent Biosciences (Nasdaq: COGT), and is a member of the board of directors of Apogee Therapeutics (Nasdaq: APGE), Spyre Therapeutics (Nasdaq: SYRE), and Oruka Therapeutics (Nasdaq: ORKA). He earned a B.B.A. from Emory University.